Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
arcticnovartis
- Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS
- Novartis to hold virtual investor event highlighting REMODEL data and remibrutinib in MS
- Phase III NEOS late-breaker will expand evidence for Kesimpta® (ofatumumab) in pediatric MS, where current approved treatment options remain limited
- New Kesimpta data from STHENOS study in treatment-naive relapsing MS and from KATHAROS breastfeeding study will be presented